BACKGROUND: Plantar warts may cause significant morbidity. Intralesional bleomycin is effective. When bleomycin is injected with a needle and syringe, it is difficult to prevent the bleomycin from infiltrating the dermis adjacent to the wart, producing unnecessary acute pain, persistent pain, and potential sloughing of normal adjacent skin. Efficacy of delivery by dermojet is not yet established. OBJECTIVES: To assess the response of recalcitrant plantar warts to bleomycin delivered by dermojet. METHODS: A total of 47 patients with 138 plantar warts present for more than 2 years and resistant to 10 cycles of cryosurgery, were recruited. Bleomycin (1 U/ml) was delivered intralesionally by dermojet at 5-week intervals for 25 weeks. RESULTS: Out of 138, 124 (89.9%) plantar warts showed complete or partial clearance after one to five sets of bleomycin injections. The recurrence rate was 6/138 (4.4%), and 8/138 (5.8%) warts failed to clear. The reduction in mean surface area of the plantar warts after each set of bleomycin injections compared to baseline surface area was statistically significant. Local side effects were similar to other methods of delivery. No systemic side effects were reported. CONCLUSIONS: This study assesses therapeutic efficacy of bleomycin delivered by dermojet in solely recalcitrant plantar warts. It provides preliminary evidence that this method of delivery may benefit a group of patients with particularly recalcitrant plantar warts and is safe and easy to use in routine dermatology practice.
BACKGROUND: Plantar warts may cause significant morbidity. Intralesional bleomycin is effective. When bleomycin is injected with a needle and syringe, it is difficult to prevent the bleomycin from infiltrating the dermis adjacent to the wart, producing unnecessary acute pain, persistent pain, and potential sloughing of normal adjacent skin. Efficacy of delivery by dermojet is not yet established. OBJECTIVES: To assess the response of recalcitrant plantar warts to bleomycin delivered by dermojet. METHODS: A total of 47 patients with 138 plantar warts present for more than 2 years and resistant to 10 cycles of cryosurgery, were recruited. Bleomycin (1 U/ml) was delivered intralesionally by dermojet at 5-week intervals for 25 weeks. RESULTS: Out of 138, 124 (89.9%) plantar warts showed complete or partial clearance after one to five sets of bleomycin injections. The recurrence rate was 6/138 (4.4%), and 8/138 (5.8%) warts failed to clear. The reduction in mean surface area of the plantar warts after each set of bleomycin injections compared to baseline surface area was statistically significant. Local side effects were similar to other methods of delivery. No systemic side effects were reported. CONCLUSIONS: This study assesses therapeutic efficacy of bleomycin delivered by dermojet in solely recalcitrant plantar warts. It provides preliminary evidence that this method of delivery may benefit a group of patients with particularly recalcitrant plantar warts and is safe and easy to use in routine dermatology practice.
Authors: Ha Ryeong Ryu; Hye-Rin Jeong; Hye-Seung Seon-Woo; Jung Soo Kim; Seul Ki Lee; Hee Joo Kim; Jin Ok Baek; Jung-Hwan Park; Joo Young Roh Journal: Drug Deliv Transl Res Date: 2018-02 Impact factor: 4.617
Authors: Francisco Miguel Camacho-Martínez; Elena Rodríguez Rey; Francisco Camacho Serrano; Adriana Wagner Journal: An Bras Dermatol Date: 2013 May-Jun Impact factor: 1.896
Authors: Daniel Chin Shiuan Lio; Rui Ning Chia; Milton Sheng Yi Kwek; Christian Wiraja; Leigh Edward Madden; Hao Chang; S Mohideen Abdul Khadir; Xiaomeng Wang; David L Becker; Chenjie Xu Journal: Sci Adv Date: 2020-05-29 Impact factor: 14.136
Authors: Aditya R Darade; Maria Lapteva; Thomas Hoffmann; Markus Mandler; Achim Schneeberger; Yogeshvar N Kalia Journal: Pharmaceutics Date: 2022-01-08 Impact factor: 6.321
Authors: Liora Bik; Martijn B A van Doorn; Neill Boeijink; Medelyn Wennekers; Arne A Meesters; Peter Bloemen; Merete Haedersdal; Albert Wolkerstorfer Journal: Lasers Surg Med Date: 2022-01-23